GlassScriptPhysician profile
Betsy Akin
NPI 1720525991
$6,028.37
in general payments reported to CMS, 2019-2025
32 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $1,248 · 2023: $1,646 · 2024: $1,222 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,341 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,341.19 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $580.82 | 2021-2025 | Leqvio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $507.90 | 2021-2024 | Lifevest |
| Abiomed | $475.13 | 2024-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $458.78 | 2024-2025 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $441.31 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $427.34 | 2022-2025 | Verquvo, Capvaxive, Belsomra |
| Atricure, INC. | $368.99 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $351.70 | 2021-2025 | Lokelma, Farxiga, Wainua |
| Amgen INC. | $305.99 | 2021-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $229.33 | 2022-2025 | Amvuttra, Onpattro |
| Boston Scientific Corporation | $227.02 | 2022-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.46 | 2021-2025 | Jardiance |
| Medtronic, INC. | $220.12 | 2022-2025 | Micra, Endurant Iis |
| Janssen Pharmaceuticals, INC | $172.68 | 2021-2023 | Xarelto |
| Becton, Dickinson and Company | $155.74 | 2025 | Channel Drain, Tridyne Vascular Sealant |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $151.01 | 2025 | |
| Daxor Corporation | $126.56 | 2022-2023 | Bva-100 |
| Nuwellis, INC. | $122.05 | 2022-2023 | Aquadex Smartflow Console |
| Vital Connect, INC | $57.39 | 2023-2024 | Vitalpatch Rtm |
| Irhythm Technologies, INC. | $55.41 | 2022 | |
| Pfizer INC. | $47.79 | 2023-2024 | |
| Scpharmaceuticals INC. | $43.25 | 2023-2025 | |
| Baxter Healthcare | $42.61 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Angiodynamics, INC. | $41.65 | 2025 | Auryon Laser System 100-120 Vac |
| Philips North America LLC | $38.00 | 2024 | (Ck4) Mcot |
| Novo Nordisk INC | $34.81 | 2022-2025 | Ozempic |
| Chiesi USA, INC. | $31.51 | 2022-2023 | Cleviprex |
| Abbott Laboratories | $29.70 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Heartflow, INC. | $25.31 | 2023 | Ffrct |
| Abbvie INC. | $13.25 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.07 | 2021 | |
| Glaxosmithkline, LLC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy Akin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.